Walgreens Boots Alliance Commences Tender Offer to Purchase Certain Outstanding Debt Securities

Walgreens Boots Alliance Commences Tender Offer to Purchase Certain Outstanding Debt Securities

DEERFIELD, Ill.–(BUSINESS WIRE)–
Walgreens Boots Alliance, Inc. (the “Company”) (Nasdaq: WBA) today announced the commencement of cash tender offers (collectively, the “Tender Offer”) for up to $2,750,000,000 aggregate principal amount of the senior notes listed in the table below (collectively, the “Notes”).

Title of Security(1)

Principal

Amount

Outstanding

CUSIP Number

Tender Caps

Acceptance

Priority Level

Early Tender

Premium(2)

Reference

U.S. Treasury

Security

Bloomberg

Reference

Page/Screen

Fixed Spread

(basis points)

 4.800% Notes due 2044

 

$1,500,000,000

 

931427AC2

 

N/A

 

1

 

$30.00

 

1.625% UST due

November 15,

2050

 

FIT1

 

138

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 4.400% Notes due 2042(3)

 

$500,000,000

 

931422AK5

 

N/A

 

2

 

$30.00

 

1.625% UST due

November 15,

2050

 

FIT1

 

130

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 4.650% Notes due 2046

 

$600,000,000

 

931427AR9

 

N/A

 

3

 

$30.00

 

1.625% UST due

November 15,

2050

 

FIT1

 

138

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 4.500% Notes due 2034

 

$500,000,000

 

931427AB4

 

N/A

 

4

 

$30.00

 

1.125% UST due

February 15,

2031

 

FIT1

 

130

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.100% Notes due 2050(4)

 

$1,000,000,000

 

931427AT5

 

$200,000,000

 

5

 

$30.00

 

1.625% UST due

November 15,

2050

 

FIT1

 

140

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.100% Notes due 2022(3)(5)

 

$1,200,000,000

 

931422AH2

 

$500,000,000

 

6

 

$30.00

 

1.500% UST due

September 15,

2022

 

FIT4

 

22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.800% Notes due 2024

 

$2,000,000,000

 

931427AH1

 

N/A

 

7

 

$30.00

 

0.250% UST due

March 15,

2024

 

FIT1

 

45

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.450% Notes due 2026

 

$1,900,000,000

 

931427AQ1

 

N/A

 

8

 

$30.00

 

0.750% UST due

March 31,

2026

 

FIT1

 

48

(1)

Subject to a limited exception, the Total Consideration will be determined taking into account the Par Call Date (as defined below), if applicable, for such series of Notes, as described herein. If such series of Notes do not have a Par Call Date, the Total Consideration will be determined based on the maturity date of the Notes of such series. In addition, Holders whose Notes are accepted will also receive Accrued Interest on such Notes.

(2)

The Total Consideration payable for each $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Deadline and accepted for purchase includes the applicable Early Tender Premium.

(3)

The 4.400% Notes due 2042 and 3.100% Notes due 2022 were issued by Walgreen Co., a wholly owned subsidiary of Walgreens Boots Alliance, Inc.

(4)

The Tender Cap of $200,000,000 for the 4.100% Notes due 2050 represents the maximum aggregate principal amount of 4.100% Notes due 2050 that may be purchased in the Offer.

(5)

The Tender Cap of $500,000,000 for the 3.100% Notes due 2022 represents the maximum aggregate principal amount of 3.100% Notes due 2022 that may be purchased in the Offer.

The Tender Offer is being made upon, and is subject to, the terms and conditions set forth in the Offer to Purchase dated April 9, 2021 (the “Offer to Purchase”). The Tender Offer will expire at 12:00 midnight, New York City time, on May 7, 2021 (one minute after 11:59 p.m. New York City time, on May 6, 2021), unless extended or earlier terminated by the Company (the “Expiration Date”). Tenders of Notes may be withdrawn at any time at or prior to 5:00 p.m., New York City time, on April 22, 2021, but may not be withdrawn thereafter except in certain limited circumstances where additional withdrawal rights are required by law.

The consideration paid in the Tender Offer for Notes that are validly tendered and accepted for purchase will be determined in the manner described in the Offer to Purchase by reference to a fixed spread over the yield to maturity of the applicable U.S. Treasury Security specified in the table above and in the Offer to Purchase (the “Total Consideration”). Holders of Notes that are validly tendered and not withdrawn at or prior to 5:00 p.m., New York City time, on April 22, 2021 (the “Early Tender Deadline”) and accepted for purchase will receive the applicable Total Consideration, which includes an early tender premium as set forth in the table above and in the Offer to Purchase (the “Early Tender Premium”). Holders of Notes who validly tender their Notes following the Early Tender Deadline and on or prior to the Expiration Date will only receive the applicable “Tender Offer Consideration,” which is an amount equal to the applicable Total Consideration minus the applicable Early Tender Premium. The Total Consideration will be determined at 10:00 a.m., New York City time, on April 23, 2021 (the “Price Determination Date”), unless extended.

Payment for Notes purchased will include accrued and unpaid interest from and including the last interest payment date applicable to the relevant series of Notes up to, but not including, the applicable settlement date for such Notes accepted for purchase. The settlement date for Notes that are validly tendered on or prior to the Early Tender Deadline is expected to be April 26, 2021, one business day following the Price Determination Date (the “Early Settlement Date”). The settlement date for the Notes that are tendered following the Early Tender Deadline but at or prior to the Expiration Date is expected to be May 11, 2021, two business days following the Expiration Date, assuming the Maximum Tender Amount is not purchased on the Early Settlement Date.

Subject to the Maximum Tender Amount and the Tender Caps, all Notes validly tendered and not validly withdrawn on or before the Early Tender Deadline having a higher Acceptance Priority Level (as shown in the table above, with 1 being the highest) will be accepted before any tendered Notes having a lower Acceptance Priority Level (with 8 being the lowest), and all Notes validly tendered after the Early Tender Deadline having a higher Acceptance Priority Level will be accepted before any Notes tendered after the Early Tender Deadline having a lower Acceptance Priority Level. However, even if the Tender Offer is not fully subscribed as of the Early Tender Deadline, subject to the Maximum Tender Amount and the Tender Caps, Notes validly tendered and not properly withdrawn at or prior to the Early Tender Deadline will be accepted for purchase in priority to other Notes tendered following the Early Tender Deadline, even if such Notes tendered following the Early Tender Deadline have a higher Acceptance Priority Level than Notes tendered at or prior to the Early Tender Deadline.

Notes of a series may be subject to proration if the aggregate principal amount of the Notes of such series validly tendered and not properly withdrawn would cause the Maximum Tender Amount or, in the case of the 4.100% Notes due 2050 and 3.100% Notes due 2022, the Tender Caps, to be exceeded. Furthermore, if the Tender Offer is fully subscribed as of the Early Tender Deadline, holders who validly tender Notes following the Early Tender Deadline but at or prior to the Expiration Date will not have any of their Notes accepted for purchase.

The Company’s obligation to accept for purchase and to pay for the Notes validly tendered in the Tender Offer is subject to the satisfaction or waiver of a number of conditions described in the Offer to Purchase, including the receipt of proceeds from the Company’s delayed draw term loan. The Company reserves the right, subject to applicable law, to: (i) waive any and all conditions to the Tender Offer; (ii) extend or terminate the Tender Offer; (iii) increase or decrease the Maximum Tender Amount and/or the Total Consideration and/or increase, decrease or eliminate the Tender Caps without extending the withdrawal deadline or otherwise reinstating withdrawal rights with respect to the Notes; or (iv) otherwise amend the Tender Offer in any respect.

Wells Fargo Securities, BofA Securities, HSBC and J.P. Morgan are acting as the dealer managers for the Tender Offer. The information agent and tender agent is Global Bondholder Services Corporation. Copies of the Offer to Purchase and related offering materials are available by contacting Global Bondholder Services Corporation by telephone at (212) 430-3774 (for banks and brokers only), (866) 470-3800 (for all others toll-free), via email at [email protected] or online at https://www.gbsc-usa.com/walgreens/. Questions regarding the Tender Offer should be directed to Wells Fargo Securities at (866) 309-6316 (toll-free) or (704) 410-4759, BofA Securities at (980) 387-3907, HSBC at (888) HSBC-4LM (toll-free) or (212) 525-5552 (collect) and J.P. Morgan at (917) 721-9052 (collect) or (866) 834-4666 (toll-free). This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. The Tender Offer is being made only pursuant to the Offer to Purchase and only in such jurisdiction as is permitted under applicable law.

Cautionary Note Regarding Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including those described in Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended August 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended February 28, 2021 and in other documents that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially. These forward-looking statements speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this press release, whether as a result of new information, future events, changes in assumptions or otherwise.

About Walgreens Boots Alliance

Walgreens Boots Alliance (Nasdaq: WBA) is a global leader in retail and wholesale pharmacy, touching millions of lives every day through dispensing and distributing medicines, its convenient retail locations, digital platforms and health and beauty products. The company has more than 100 years of trusted health care heritage and innovation in community pharmacy and pharmaceutical wholesaling.

Including equity method investments, WBA has a presence in more than 25 countries, employs more than 450,000 people and has more than 21,000 stores.

WBA’s purpose is to help people across the world lead healthier and happier lives. The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA is a Participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. WBA is included in FORTUNE’s 2021 list of the World’s Most Admired Companies. This is the 28th consecutive year that WBA or its predecessor company, Walgreen Co., has been named to the list.

*© 2021, Fortune Media IP Limited. Used under license.

(WBA-GEN)

Media Relations

USA / Morry Smulevitz +1 847 315 0517

International +44 (0)20 7980 8585

Investor Relations

Gerald Gradwell and Jay Spitzer +1 847 315 2922

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Medical Supplies Retail Health Other Retail Department Stores Specialty Pharmaceutical

MEDIA:

Logo
Logo

IIROC Trade Resumption – ONC

Canada NewsWire

TORONTO, April 9, 2021 /CNW/ – Trading resumes in:

Company: Oncolytics Biotech Inc.

TSX Symbol: ONC

All Issues: No

Resumption (ET): 11:23:00 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

UPCOMING DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Infinity Q Capital Management LLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PR Newswire

LOS ANGELES, April 9, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Q Capital Management LLC (“Infinity Q” of “the Company”) on behalf of investors in Infinity Q Diversified Alpha Fund Institutional Class shares (NASDAQ: IQDNX) or Infinity Q Diversified Alpha Fund Investor Class shares (NASDAQ: IQDAX) for violations of the federal securities laws.

Investors who purchased the Company’s securities between December 21, 2018 and February 22, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before April 27, 2021. 

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Infinity Q’s Chief Investment Officer adjusted parameters related to its third-party pricing model which impacted the valuation of swaps held by the Company. As a result of the change, the Company was incapable of calculating a proper NAV. The change also made past reported NAVs unreliable. The Company halted redemptions and liquidate its assets as a result of the change. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Infinity Q, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/upcoming-deadline-alert-the-schall-law-firm-reminds-investors-of-a-class-action-lawsuit-against-infinity-q-capital-management-llc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-301265938.html

SOURCE The Schall Law Firm

IIROC Trading Halt – ONC

Canada NewsWire

TORONTO, April 9, 2021 /CNW/ – The following issues have been halted by IIROC:

Company: Oncolytics Biotech Inc.

TSX Symbol: ONC

All Issues: No

Reason: Single-Stock Circuit Breaker

Halt Time (ET): 11:18:00 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Tekla World Healthcare Fund Declares Monthly Cash Distribution

Tekla World Healthcare Fund Declares Monthly Cash Distribution

BOSTON–(BUSINESS WIRE)–
On April 9, 2021, Tekla World Healthcare Fund declared its monthly cash distribution of $0.1167 per share. The record date for the monthly cash distribution is April 20, 2021 and the payable date is April 30, 2021. The Fund will trade ex-distribution on April 19, 2021.

Note that only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan (“DRIP”) will have cash distributions automatically reinvested in shares of the Fund.

Tekla World Healthcare Fund (NYSE: THW) is a closed-end fund that invests in companies in the healthcare industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.

Please contact Destra Capital Advisors, the Fund’s marketing and investor support services agent, at [email protected] or call (877)855-3434 if you have any questions regarding THW.

Destra Capital Advisors

[email protected]

(877)855-3434

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Tekla Healthcare Opportunities Fund Declares Monthly Cash Distribution

Tekla Healthcare Opportunities Fund Declares Monthly Cash Distribution

BOSTON–(BUSINESS WIRE)–
On April 9, 2021, Tekla Healthcare Opportunities Fund declared its monthly cash distribution of $0.1125 per share. The record date for the monthly cash distribution is April 20, 2021 and the payable date is April 30, 2021. The Fund will trade ex-distribution on April 19, 2021.

Note that only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan (“DRIP”) will have cash distributions automatically reinvested in shares of the Fund.

Tekla Healthcare Opportunities Fund (NYSE: THQ) is a closed-end fund that invests in companies in the healthcare industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.

Please contact Destra Capital Advisors, the Fund’s marketing and investor support services agent, at [email protected] or call (877)855-3434 if you have any questions regarding THQ.

Destra Capital Advisors

[email protected]

(877) 855-3434

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Century Bancorp, Inc. Buyout

WILMINGTON, Del., April 09, 2021 (GLOBE NEWSWIRE) — Rigrodsky Law, P.A. announces that it is investigating Century Bancorp, Inc. (“Century Bancorp”) (NASDAQ GS: CNBKA) regarding possible breaches of fiduciary duties and other violations of law related to Century Bancorp’s agreement to be acquired by Eastern Bankshares, Inc. (“Eastern Bankshares”) (NASDAQ GS: EBC). Under the terms of the agreement, Century Bancorp’s shareholders will receive $115.28 in cash per share.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-century-bancorp-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky Law, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Centerra Gold 2021 First Quarter Results Conference Call and Annual Meeting of Shareholders Details

TORONTO, April 09, 2021 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra”) (TSX: CG) will host a conference call and webcast to discuss the 2021 first quarter operating and financial results on Tuesday, May 11, 2021 at 8:30 a.m. (Toronto time). The quarterly results are scheduled to be released before the market opens on Tuesday, May 11, 2021. The Company will also host its 2021 Annual Meeting of Shareholders on May 11, 2021 at 11:00 a.m. (Toronto time) in a virtual only format.


2021 First Quarter Results Conference Call and Webcast


Tuesday, May 11, 2021 at 8:30 a.m. (Toronto Time), call-in numbers are as follows:

  • North American participants: toll-free number +1 (800) 582-1443
  • International participants call: +1 (212) 231-2910
  • The conference call is being audio webcast by Intrado and can be accessed live at Centerra Gold’s website at: www.centerragold.com
  • Presentation slides of the first quarter results will also be accessible on Centerra Gold’s website at www.centerragold.com

An audio recording of the call will be available approximately two hours after the call via telephone until midnight Eastern Time on Tuesday, May 18, 2021. The recording can be accessed by calling (416) 626-4100 or (800) 558-5253 and using the passcode 21993267. In addition, the webcast will be archived on Centerra Gold’s website www.centerragold.com.


Virtual Annual Meeting of Shareholders


Centerra’s Annual Meeting of Shareholders will be held on Tuesday, May 11, 2021 at 11:00 a.m. (Toronto time). This year, out of an abundance of caution, the Annual Meeting will be held in a virtual only format, to proactively deal with the unprecedented public health impact of COVID-19 and to mitigate risks to the health and safety of our shareholders, employees and other stakeholders.

The Virtual Annual Meeting will be available online at: https://web.lumiagm.com/444191289.   

The link to the virtual meeting will also be accessible at www.centerragold.com and will be archived for later use.

Voting and participation instructions for eligible shareholders are provided in the Company’s Notice of Annual Meeting of Shareholders and the Management Information Circular. The Annual Meeting materials were mailed to shareholders of record and are available on the Company’s website at: http://www.centerragold.com/2021-meeting-materials and on SEDAR at www.sedar.com.

About Centerra

Centerra Gold Inc. is a Canadian-based gold mining company focused on operating, developing, exploring and acquiring gold properties in North America, Asia and other markets worldwide and is one of the largest Western-based gold producers in Central Asia. Centerra operates three mines, the Kumtor Mine in the Kyrgyz Republic, the Mount Milligan Mine in British Columbia, Canada and the Öksüt Mine in Turkey. Centerra’s shares trade on the Toronto Stock Exchange (TSX) under the symbol CG. The Company is based in Toronto, Ontario, Canada.

Additional information

Additional information on Centerra is available on the Company’s website at www.centerragold.com and on SEDAR at www.sedar.com.

For further information, please contact:

John W. Pearson
Vice President, Investor Relations
Centerra Gold Inc.
416-204-1953
[email protected]

A PDF accompanying this announcement is available at http://ml.globenewswire.com/Resource/Download/6dd83284-82b9-49f0-9642-97f063f79ec2



Genetic Technologies Provides Update on COVID-19 Risk Test Launch

MELBOURNE, Australia, April 09, 2021 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business provides an update to the market on the progress of the US commercial availability of the Company’s COVID-19 Serious Disease Risk (“COVID-19 Risk Test”) via US Based Infinity BiologiX LLC (‘IBX’), (ref: ASX Announcement 3 March 2021).

Genetic Technologies advises that the Company has completed all validation and data-based analysis for the COVID-19 Risk Test. IBX, our US based distribution partner is currently completing the technical interface with their telehealth partner for the commercial availability of the COVID-19 Risk Test across the United States.

The technical interface is a requirement for the submission to Centres for Medicare and Medicaid Services (‘CMS’), with submission required prior to the commercial release of the COVID-19 Risk Test by IBX.

IBX has three well-established labs, with two in New Jersey and one in Minnesota and a network of COVID-19 testing partners, with access to testing sites across the country providing a clear pathway for the sale and distribution of GTG’s COVID-19 Risk Test.

GTG’s COVID-19 Risk Test may enable the risk assessment of an individual developing a serious disease should they contract the COVID-19 virus.  The COVID-19 Risk Test is intended to predict ‘disease severity’ using a combination of genetic and clinical information.

“Our COVID-19 Risk Test is a crucial product that will provide individuals with the ability to understand their personal risk associated with contracting a serious case of this disease,” commented Simon Morriss, CEO of GTG. “Alongside existing treatment options and vaccines, we believe this test will enable more insightful decisions for states, workplaces and individuals on pathways forward in managing this pandemic.”

IBX is a market-disrupting central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas.

IBX launched its COVID-19 saliva-test in May 2020, after receiving FDA Emergency Use Authorization. It was the first test to utilize saliva as the primary biomaterial for SARS-CoV-2, and IBX subsequently became the first company to offer an at-home collection with this approach.

IBX currently has the capacity to process over 100,000 COVID-19 Risk Tests per day across its two major labs and is well-positioned with an existing network of SARS-CoV-2 testing partners and associated medical practitioners across the US to be able to use GTG’s COVID-19 Risk Test in conjunction with these existing third-party SARS-CoV-2 Tests.

Further updates will be provided in due course.

Authorised by the Board of Genetic Technologies

Investor Relations (AUS)    Investor Relations and Media (US)
Stephanie Ottens     Dave Gentry
Market Eye   1 800 RED CHIP (733 2447)
M: +61 434 405 400     Cell: 407 491 4498
E: [email protected]                E: [email protected]

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.gtglabs.com

About Infinity BiologiX:

Infinity BiologiX (IBX) is a market-disrupting next-generation central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas. IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020.

For more information, visit www.ibx.bio



Superior Plus Announces Completion of the Sale of its Specialty Chemicals Business, Amendment and Extension of its Syndicated Credit Facility and Details for the 2021 Virtual Investor Day

Superior Plus Announces Completion of the Sale of its Specialty Chemicals Business, Amendment and Extension of its Syndicated Credit Facility and Details for the 2021 Virtual Investor Day

TORONTO–(BUSINESS WIRE)–
Superior Plus Corp. (“Superior”)(TSX:SPB) is pleased to announce the completion of the previously announced sale of its Specialty Chemicals business (“Specialty Chemicals”) to Birch Hill Equity Partners (“Birch Hill”) for total consideration of $725 million (the “Transaction”). Under the terms of the Transaction, Superior received $600 million in cash proceeds from Birch Hill, subject to certain adjustments, and $125 million in the form of a 6% unsecured note issued by the affiliate of Birch Hill that is acquiring Specialty Chemicals. The consideration received is subject to certain post-closing adjustments as previously disclosed.

“We are excited to announce the close of the Transaction as this represents the completion of Superior’s transformation into a pure-play energy distribution company,” said Luc Desjardins, President and CEO of Superior. “The sale of Specialty Chemicals was an important component of our strategic plan and provides us with additional capital to further accelerate our accretive growth strategy in the U.S. and Canadian propane markets. We have a robust pipeline of acquisition opportunities and we anticipate more than doubling the U.S. Propane Distribution EBITDA from operations over the next five years.”

Orrick, Herrington & Sutcliffe LLP acted as legal counsel to Superior on the Transaction. Barclays acted as financial advisor to Superior.

Amended Senior Secured Credit Facility

Superior is also pleased to announce that its wholly-owned subsidiaries, Superior Plus LP, Superior General Partner Inc. and Superior Plus US Financing Inc., have completed an extension of their $750 million senior secured revolving credit facility (the “Credit Facility”) with The Bank of Nova Scotia and TD Securities as Co-Lead Arrangers, and a syndicate of ten lenders. The Credit Facility will now mature on May 8, 2026 and has been amended to reflect the release of certain obligors from its terms as a result of the Transaction. There have been no changes to the total commitments available under the Credit Facility ($750 million), the accordion facility capacity ($300 million) or the financial covenants.

“We are pleased to have completed the extension of the Credit Facility with strong support from our lenders. Superior continues to maintain its financial flexibility and low borrowing costs to support our Energy Distribution growth strategy through acquisitions and organic growth. Our strong balance sheet, along with prudent financial policies, supports our ability to pursue accretive growth opportunities to create long-term value for our shareholders,” said Beth Summers, Executive Vice President and CFO.

Superior is committed to maintaining a resilient balance sheet with sufficient liquidity to grow the business through acquisitions and organic growth. Superior plans to use the net proceeds from the Transaction initially to reduce debt, including paying down outstanding loans under the Credit Facility. As a result of the Transaction, Superior’s available liquidity based on borrowing capacity under the Credit Facility and cash on hand is approximately $1.2 billion. Superior expects to use the available liquidity for additional debt repayment and acquisitions.

2021 Virtual Investor Day

Superior will host a virtual Investor Day on May 25, 2021 at 1 PM EDT. During the event, members of the executive leadership team will provide an update on Superior’s markets and businesses, strategic transformational initiative, the Superior Way Forward, and future financial outlook.

To confirm your attendance for the event, please RSVP by emailing [email protected]. A link to the webcast along with the agenda for the event will be emailed to all participants and will also be posted on Superior’s website in the “Events” section closer to the time of Investor Day.

About the Corporation

Superior is a leading North American distributor and marketer of propane and distillates and related products and services, servicing over 780,000 customer locations in the U.S. and Canada.

For further information about Superior, please visit our website at: www.superiorplus.com or contact: Beth Summers, Executive Vice President and Chief Financial Officer, Tel: (416) 340-6015, or Rob Dorran, Vice President, Investor Relations and Treasurer, Tel: (416) 340-6003, E-mail: [email protected], Toll Free: 1-866-490-PLUS (7587).

Forward Looking Information

Certain information included herein is forward-looking, within the meaning of applicable Canadian securities laws. Such information is typically identified by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “plan,” “intend,” “forecast,” “future,” “guidance,” “may,” “predict,” “project,” “should,” “strategy,” “target,” “will” or similar expressions suggesting future outcomes. Forward-looking information in this news release includes forward looking information relating to the use of proceeds from the Transaction, the anticipation that the U.S. Propane Distribution EBITDA from operations will more than double over the next five years and the use of available liquidity for additional debt repayment and acquisitions. Superior believes the expectations reflected in such forward-looking information are reasonable but no assurance can be given that these expectations will prove to be correct and such information should not be unduly relied upon.

Forward-looking information is not a guarantee of future performance. By its very nature, forward-looking information involves inherent assumptions, risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking information will not be achieved, including risks relating to the operating and financial performance of the Energy Distribution business which are described in Superior’s annual management discussion and analysis and Superior’s current annual information form for the fiscal year ended December 31, 2020 and risks relating to the availability of and ability to execute sufficient energy distribution acquisitions on attractive terms over the next five years. Key assumptions or risk factors to the anticipated ability to execute sufficient acquisitions, and more than double U.S. Propane Distribution EBITDA from operations, in the next five years include, but are not limited to, financial market conditions, Superior’s future debt levels, Superior’s ability to generate sufficient cash flows from operations to meet its current and future obligations, access to, and terms of, future sources of funding for Superior’s capital expenditures and acquisitions, future adjustments to the consideration received from the Transaction, the integration of businesses into Superior’s operations, competitive action by other companies, availability and timing of acquisition targets, actions by governmental authorities including increases in taxes and changes in environmental and other regulations, general economic, market and business conditions, the regulatory framework that governs the operations of Superior’s business and industry capacity. Should one or more of these risks and uncertainties materialize, or should assumptions described above prove incorrect, Superior’s actual performance and results in future periods may differ materially from any projections of future performance or results expressed or implied by such forward-looking information. We caution readers not to place undue reliance on this information as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives, expectations and anticipations, estimates and intentions expressed in such forward-looking information.

Forward-looking information contained in this news release is provided for the purpose of providing information about management’s goals, plans and range of expectations for the future and may not be appropriate for other purposes. Any forward-looking information is made as of the date hereof and, except as required by law, Superior does not undertake any obligation to publicly update or revise such information to reflect new information, subsequent or otherwise.

Non-GAAP Measures

Throughout this release, Superior has used the following terms that are not defined by International Financial Reporting Standards (“Non-GAAP Financial Measures”), but are used by management to evaluate the performance of Superior and its business: earnings before interest, taxes, depreciation and amortization (“EBITDA”) and EBITDA from operations. These measures may also provide additional useful information to and be used by investors, financial institutions and credit rating agencies to assess Superior’s performance and ability to service debt. Non-GAAP Financial Measures do not have standardized meanings prescribed by GAAP and are therefore unlikely to be comparable to similar measures presented by other companies as they may calculate them differently from Superior. Securities regulations require that Non-GAAP Financial Measures are clearly defined, qualified and reconciled to their most comparable GAAP financial measures.

Non-GAAP Financial Measures should not, therefore, be considered in isolation or used in substitute for measures of performance prepared in accordance with GAAP. Investors should be cautioned that EBITDA from operations should not be construed as an alternative to net earnings, cash flow from operating activities or other measures of financial results determined in accordance with GAAP as an indicator of Superior’s performance. Non-GAAP Financial Measures are identified and defined as follows:

EBITDA from operations

EBITDA from operations represents earnings before interest, taxes, depreciation, amortization, gains and losses on disposal of assets, finance expense, restructuring costs, transaction and other costs, unrealized gains and losses on derivative financial instruments, realized gains and losses on foreign currency hedging contracts, and corporate costs. EBITDA from operations excludes costs that are not considered representative of Superior’s underlying core operating performance. Management uses EBITDA from operations to set targets for Superior (including annual guidance and variable compensation targets).

Beth Summers

Executive Vice President and Chief Financial Officer

Tel: (416) 340-6015

or

Rob Dorran

Vice President, Investor Relations and Treasurer

Tel: (416) 340-6003

E-mail: [email protected]

Toll Free: 1-866-490-PLUS (7587)

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Retail Specialty Energy Oil/Gas

MEDIA:

Logo
Logo